CCEL vs IART vs NTRA vs LMAT

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus 1. 5% for Integra LifeSciences Holdings Corporation (IART). LeMaitre Vascular, Inc. (LMAT) offers the better valuation at 42. 8x trailing P/E (37. 2x forward), making it the more compelling value choice. Analysts rate Integra LifeSciences Holdings Corporation (IART) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, LeMaitre Vascular, Inc.

(LMAT) is the cheapest at 42. 8x versus Cryo-Cell International, Inc. at 69. 0x. On forward P/E, Integra LifeSciences Holdings Corporation is actually cheaper at 5. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, LeMaitre Vascular, Inc.

(LMAT) delivered a total return of +118. 2%, compared to -81. 7% for Integra LifeSciences Holdings Corporation (IART). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus IART's -63. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cryo-Cell International, Inc.

(CCEL) is the lower-risk stock at 0. 35β versus Integra LifeSciences Holdings Corporation's 2. 34β — meaning IART is approximately 565% more volatile than CCEL relative to the S&P 500. On balance sheet safety, Natera, Inc. (NTRA) carries a lower debt/equity ratio of 13% versus 195% for Integra LifeSciences Holdings Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 35. 9% versus 1. 5% for Integra LifeSciences Holdings Corporation (IART). On earnings-per-share growth, the picture is similar: Cryo-Cell International, Inc. grew EPS 104. 4% year-over-year, compared to -73. 6% for Integra LifeSciences Holdings Corporation. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

LeMaitre Vascular, Inc.

(LMAT) is the more profitable company, earning 23. 1% net margin versus -31. 6% for Integra LifeSciences Holdings Corporation — meaning it keeps 23. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LMAT leads at 27. 2% versus -13. 4% for NTRA. At the gross margin level — before operating expenses — CCEL leads at 75. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Integra LifeSciences Holdings Corporation (IART) trades at 5.

8x forward P/E versus 37. 2x for LeMaitre Vascular, Inc. — 31. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NTRA: 19. 4% to $262. 50.

In this comparison, CCEL (7.

1% yield), LMAT (0. 7% yield) pay a dividend. IART, NTRA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, LeMaitre Vascular, Inc.

(LMAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 57), 0. 7% yield, +608. 6% 10Y return). Integra LifeSciences Holdings Corporation (IART) carries a higher beta of 2. 34 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LMAT: +608. 6%, IART: -63. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CCEL is a small-cap income-oriented stock; IART is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock; LMAT is a small-cap quality compounder stock. CCEL, LMAT pay a dividend while IART, NTRA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.